{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T06:44:19Z","timestamp":1794638659442,"version":"4.9.1"},"reference-count":103,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T00:00:00Z","timestamp":1707868800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["esmogastro.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Gastrointestinal Oncology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.esmogo.2024.100048","type":"journal-article","created":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T21:43:24Z","timestamp":1714167804000},"page":"100048","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Role of the microbiome in the development and treatment of gastric cancer: an overview of the biological and clinical landscape"],"prefix":"10.1016","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7297-9110","authenticated-orcid":false,"given":"C.A.","family":"Cella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Ciardiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3313-8527","authenticated-orcid":false,"given":"L.","family":"Gervaso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1274-5643","authenticated-orcid":false,"given":"H.","family":"van Laarhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Nezi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Catozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8591-9339","authenticated-orcid":false,"given":"F.","family":"Lordick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Smyth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2722-822X","authenticated-orcid":false,"given":"S.","family":"de Pascale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Benini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1150-0345","authenticated-orcid":false,"given":"C.","family":"Valenza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6618-8598","authenticated-orcid":false,"given":"L.","family":"Guidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Fumagalli Romario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6869-0704","authenticated-orcid":false,"given":"N.","family":"Fazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmogo.2024.100048_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101404","article-title":"The current and future incidence and mortality of gastric cancer in 185 countries, 2020-40: a population-based modelling study","volume":"47","author":"Morgan","year":"2022","journal-title":"EClinicalMedicine"},{"issue":"1","key":"10.1016\/j.esmogo.2024.100048_bib2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.esmogo.2024.100048_bib3","doi-asserted-by":"crossref","DOI":"10.1177\/10732748221099227","article-title":"Recent estimates and predictions of 5-year survival in patients with gastric cancer: a model-based period analysis","volume":"29","author":"Li","year":"2022","journal-title":"Cancer Control"},{"issue":"3","key":"10.1016\/j.esmogo.2024.100048_bib4","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3390\/cancers11030399","article-title":"Perioperative treatment in resectable gastric cancer: current perspectives and future directions","volume":"11","author":"Petrillo","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10.1016\/j.esmogo.2024.100048_bib5","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1038\/sj.bjc.6602573","article-title":"A\u00a0phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients","volume":"92","author":"De Vita","year":"2005","journal-title":"Br J Cancer"},{"issue":"9742","key":"10.1016\/j.esmogo.2024.100048_bib6","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"issue":"10294","key":"10.1016\/j.esmogo.2024.100048_bib7","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.esmogo.2024.100048_bib8","first-page":"1321","article-title":"Beyond median overall survival: estimating trends for multiple survival scenarios in patients with metastatic esophagogastric cancer","volume":"20","author":"Pape","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.esmogo.2024.100048_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2022.999001","article-title":"Human gut microbiota in health and disease: unveiling the relationship","volume":"13","author":"Afzaal","year":"2022","journal-title":"Front Microbiol"},{"issue":"5","key":"10.1016\/j.esmogo.2024.100048_bib10","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1593\/tlo.13412","article-title":"Colon macrophages polarized by commensal bacteria cause colitis and cancer through the bystander effect","volume":"6","author":"Yang","year":"2013","journal-title":"Transl Oncol"},{"issue":"10","key":"10.1016\/j.esmogo.2024.100048_bib11","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1007\/s11912-014-0406-0","article-title":"Cancer-promoting effects of microbial dysbiosis","volume":"16","author":"Sheflin","year":"2014","journal-title":"Curr Oncol Rep"},{"issue":"8336","key":"10.1016\/j.esmogo.2024.100048_bib12","first-page":"1273","article-title":"Unidentified curved bacilli on gastric epithelium in active chronic gastritis","volume":"1","author":"Warren","year":"1983","journal-title":"Lancet"},{"issue":"8390","key":"10.1016\/j.esmogo.2024.100048_bib13","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S0140-6736(84)91816-6","article-title":"Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration","volume":"1","author":"Marshall","year":"1984","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.esmogo.2024.100048_bib14","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1128\/CMR.00011-10","article-title":"Helicobacter pylori and gastric cancer: factors that modulate disease risk","volume":"23","author":"Wroblewski","year":"2010","journal-title":"Clin Microbiol Rev"},{"issue":"11","key":"10.1016\/j.esmogo.2024.100048_bib15","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1056\/NEJMoa001999","article-title":"Helicobacter pylori infection and the development of gastric cancer","volume":"345","author":"Uemura","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.esmogo.2024.100048_bib16","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1053\/j.gastro.2023.04.026","article-title":"Effect of Helicobacter pylori eradication therapy on the incidence of noncardia gastric adenocarcinoma in a large diverse population in the United States","volume":"165","author":"Li","year":"2023","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.esmogo.2024.100048_bib17","doi-asserted-by":"crossref","first-page":"60","DOI":"10.15430\/JCP.2016.21.1.60","article-title":"Comparison of gastric microbiota between gastric juice and mucosa by next generation sequencing method","volume":"21","author":"Sung","year":"2016","journal-title":"J\u00a0Cancer Prev"},{"issue":"suppl 1","key":"10.1016\/j.esmogo.2024.100048_bib18","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1111\/j.1753-4887.2012.00493.x","article-title":"Defining the human microbiome","volume":"70","author":"Ursell","year":"2012","journal-title":"Nutr Rev"},{"issue":"1","key":"10.1016\/j.esmogo.2024.100048_bib19","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3390\/microorganisms7010014","article-title":"What is the healthy gut microbiota composition? A changing ecosystem across age, environment, diet, and diseases","volume":"7","author":"Rinninella","year":"2019","journal-title":"Microorganisms"},{"key":"10.1016\/j.esmogo.2024.100048_bib20","doi-asserted-by":"crossref","first-page":"8228","DOI":"10.1128\/AEM.71.12.8228-8235.2005","article-title":"UniFrac: a new phylogenetic method for comparing microbial communities","volume":"71","author":"Knight","year":"2005","journal-title":"Appl Environ Microbiol"},{"issue":"5","key":"10.1016\/j.esmogo.2024.100048_bib21","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1136\/gutjnl-2021-326789","article-title":"Gut microbiome and health: mechanistic insights","volume":"71","author":"de Vos","year":"2022","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.esmogo.2024.100048_bib22","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2174\/138920009787048392","article-title":"The effect of proton pump inhibitors on the human microbiota","volume":"10","author":"Vesper","year":"2009","journal-title":"Curr Drug Metab"},{"issue":"3","key":"10.1016\/j.esmogo.2024.100048_bib23","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1177\/2050640614566846","article-title":"The human gastric microbiota: is it time to rethink the pathogenesis of stomach diseases?","volume":"3","author":"Nardone","year":"2015","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.esmogo.2024.100048_bib24","article-title":"Role of the gastric microbiome in gastric cancer: from carcinogenesis to treatment","volume":"12","author":"Yang","year":"2021","journal-title":"Front Microbiol"},{"issue":"1","key":"10.1016\/j.esmogo.2024.100048_bib25","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1590\/S1807-59322007000100008","article-title":"Digestive tract microbiota in healthy volunteers","volume":"62","author":"Zilberstein","year":"2007","journal-title":"Clinics (Sao Paulo)"},{"issue":"suppl 1","key":"10.1016\/j.esmogo.2024.100048_bib26","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/hel.12260","article-title":"Gastric microbiota","volume":"20","author":"Ianiro","year":"2015","journal-title":"Helicobacter"},{"issue":"3","key":"10.1016\/j.esmogo.2024.100048_bib27","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1073\/pnas.0506655103","article-title":"Molecular analysis of the bacterial microbiota in the human stomach","volume":"103","author":"Bik","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"10.1016\/j.esmogo.2024.100048_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0007985","article-title":"Bacterial microbiota profiling in gastritis without Helicobacter pylori infection or non-steroidal anti-inflammatory drug use","volume":"4","author":"Li","year":"2009","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.esmogo.2024.100048_bib29","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.micpath.2012.03.008","article-title":"Comparative analysis of gastric bacterial microbiota in Mongolian gerbils after long-term infection with Helicobacter pylori","volume":"53","author":"Osaki","year":"2012","journal-title":"Microb Pathog"},{"key":"10.1016\/j.esmogo.2024.100048_bib30","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/610421","article-title":"Culturable bacterial microbiota of the stomach of Helicobacter pylori positive and negative gastric disease patients","volume":"2014","author":"Khosravi","year":"2014","journal-title":"ScientificWorldJournal"},{"issue":"4","key":"10.1016\/j.esmogo.2024.100048_bib31","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/ismej.2010.149","article-title":"Structure of the human gastric bacterial community in relation to Helicobacter pylori status","volume":"5","author":"Maldonado-Contreras","year":"2011","journal-title":"ISME J"},{"issue":"21","key":"10.1016\/j.esmogo.2024.100048_bib32","doi-asserted-by":"crossref","first-page":"5317","DOI":"10.3390\/cancers14215317","article-title":"Gut microbiota and tumor immune escape: a new perspective for improving tumor immunotherapy","volume":"14","author":"He","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"Pt 3","key":"10.1016\/j.esmogo.2024.100048_bib33","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.semcancer.2022.05.001","article-title":"Microbiota and gastric cancer","volume":"86","author":"Bess\u00e8de","year":"2022","journal-title":"Semin Cancer Biol"},{"issue":"8","key":"10.1016\/j.esmogo.2024.100048_bib34","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1172\/JCI118993","article-title":"Processing and proliferative effects of human progastrin in transgenic mice","volume":"98","author":"Wang","year":"1996","journal-title":"J\u00a0Clin Invest"},{"issue":"1","key":"10.1016\/j.esmogo.2024.100048_bib35","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1053\/j.gastro.2010.09.048","article-title":"Lack of commensal flora in Helicobacter pylori-infected INS-GAS mice reduce gastritis and delays intraepithelial neoplasia","volume":"140","author":"Lofgren","year":"2011","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.esmogo.2024.100048_bib36","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1136\/gutjnl-2013-305178","article-title":"Gastric colonisation with a restricted commensal microbiota replicates the promotion of neoplastic lesions by diverse intestinal microbiota in the Helicobacter pylori INS-GAS mouse model of gastric carcinogenesis","volume":"63","author":"Lertpiriyapong","year":"2014","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.esmogo.2024.100048_bib37","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1136\/gutjnl-2017-314205","article-title":"Gastric microbial community profiling reveals a dysbiotic cancer-associated microbiota","volume":"67","author":"Ferreira","year":"2018","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.esmogo.2024.100048_bib38","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1136\/gutjnl-2017-314281","article-title":"Mucosal microbiome dysbiosis in gastric carcinogenesis","volume":"67","author":"Coker","year":"2018","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.esmogo.2024.100048_bib39","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/MEG.0000000000000542","article-title":"Bacterial overgrowth and diversification of microbiota in gastric cancer","volume":"28","author":"Wang","year":"2016","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.esmogo.2024.100048_bib40","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1038\/s41598-022-08288-9","article-title":"Dysbiotic change in gastric microbiome and its functional implication in gastric carcinogenesis","volume":"12","author":"Park","year":"2022","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.esmogo.2024.100048_bib41","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s12866-022-02594-y","article-title":"Analysis of gastric microbiome reveals three distinctive microbial communities associated with the occurrence of gastric cancer","volume":"22","author":"Liu","year":"2022","journal-title":"BMC Microbiol"},{"issue":"5","key":"10.1016\/j.esmogo.2024.100048_bib42","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1080\/19490976.2020.1762520","article-title":"The role of gastric microbiota in gastric cancer","volume":"11","author":"Stewart","year":"2020","journal-title":"Gut Microbes"},{"issue":"1","key":"10.1016\/j.esmogo.2024.100048_bib43","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-16289-2","article-title":"Dysbiosis of the microbiome in gastric carcinogenesis","volume":"7","author":"Casta\u00f1o-Rodr\u00edguez","year":"2017","journal-title":"Sci Rep"},{"issue":"3-4","key":"10.1016\/j.esmogo.2024.100048_bib44","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0165-1218(91)90123-4","article-title":"Carcinogenic N-nitrosamines in the diet: occurrence, formation, mechanisms and carcinogenic potential","volume":"259","author":"Tricker","year":"1991","journal-title":"Mutat Res"},{"issue":"1","key":"10.1016\/j.esmogo.2024.100048_bib45","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.syapm.2016.10.001","article-title":"Detection, isolation and characterization of Fusobacterium gastrosuis sp. nov. colonizing the stomach of pigs","volume":"40","author":"De Witte","year":"2017","journal-title":"Syst Appl Microbiol"},{"issue":"2","key":"10.1016\/j.esmogo.2024.100048_bib46","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1101\/gr.126516.111","article-title":"Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma","volume":"22","author":"Castellarin","year":"2012","journal-title":"Genome Res"},{"issue":"12","key":"10.1016\/j.esmogo.2024.100048_bib47","first-page":"3885","article-title":"Could periodontal disease through periopathogen fusobacterium nucleatum be an aggravating factor for gastric cancer?","volume":"9","author":"\u0218urlin","year":"2020","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.esmogo.2024.100048_bib48","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.3389\/fmicb.2019.01261","article-title":"Mucosa-associated microbiota in gastric cancer tissues compared with non-cancer tissues","volume":"10","author":"Chen","year":"2019","journal-title":"Front Microbiol"},{"issue":"4","key":"10.1016\/j.esmogo.2024.100048_bib49","first-page":"1023","article-title":"Comparison of clinicopathological parameters, prognosis, micro-ecological environment and metabolic function of gastric cancer with or without Fusobacterium sp. infection","volume":"12","author":"Nie","year":"2021","journal-title":"J\u00a0Cancer"},{"key":"10.1016\/j.esmogo.2024.100048_bib50","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-73448-8","article-title":"Fusobacterium nucleatum is associated with worse prognosis in Lauren\u2019s diffuse type gastric cancer patients","volume":"10","author":"Boehm","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.esmogo.2024.100048_bib51","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ebiom.2018.12.034","article-title":"Alterations of gastric mucosal microbiota across different stomach microhabitats in a cohort of 276 patients with gastric cancer","volume":"40","author":"Liu","year":"2019","journal-title":"EBioMedicine"},{"issue":"4","key":"10.1016\/j.esmogo.2024.100048_bib52","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/path.4782","article-title":"Propionibacterium acnes overabundance and natural killer group 2 member D system activation in corpus-dominant lymphocytic gastritis","volume":"240","author":"Montalban-Arques","year":"2016","journal-title":"J\u00a0Pathol"},{"issue":"1","key":"10.1016\/j.esmogo.2024.100048_bib53","doi-asserted-by":"crossref","DOI":"10.1111\/hel.12547","article-title":"Evaluation of gastric microbiome and metagenomic function in patients with intestinal metaplasia using 16S rRNA gene sequencing","volume":"24","author":"Park","year":"2019","journal-title":"Helicobacter"},{"issue":"7164","key":"10.1016\/j.esmogo.2024.100048_bib54","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/nature06187","article-title":"Helicobacter exploits integrin for type IV secretion and kinase activation","volume":"449","author":"Kwok","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.esmogo.2024.100048_bib55","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3389\/fcimb.2018.00433","article-title":"The gastric microbiome is perturbed in advanced gastric adenocarcinoma identified through shotgun metagenomics","volume":"8","author":"Hu","year":"2018","journal-title":"Front Cell Infect Microbiol"},{"issue":"10","key":"10.1016\/j.esmogo.2024.100048_bib56","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","article-title":"Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Lordick","year":"2022","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.esmogo.2024.100048_bib57","doi-asserted-by":"crossref","first-page":"167","DOI":"10.6004\/jnccn.2022.0008","article-title":"Gastric cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Ajani","year":"2022","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"3","key":"10.1016\/j.esmogo.2024.100048_bib58","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.jcmgh.2021.08.013","article-title":"The role of microbiota in gastrointestinal cancer and cancer treatment: chance or curse?","volume":"13","author":"Smet","year":"2022","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.esmogo.2024.100048_bib59","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/j.surg.2021.10.014","article-title":"Impact of gastrointestinal surgery upon the gut microbiome: a systematic review","volume":"171","author":"Tarazi","year":"2022","journal-title":"Surgery"},{"issue":"2","key":"10.1016\/j.esmogo.2024.100048_bib60","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.diabet.2013.11.003","article-title":"Gastrointestinal changes after bariatric surgery","volume":"40","author":"Quercia","year":"2014","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.esmogo.2024.100048_bib61","doi-asserted-by":"crossref","DOI":"10.1038\/srep20701","article-title":"Gastric microbiota and predicted gene functions are altered after subtotal gastrectomy in patients with gastric cancer","volume":"6","author":"Tseng","year":"2016","journal-title":"Sci Rep"},{"issue":"7","key":"10.1016\/j.esmogo.2024.100048_bib62","doi-asserted-by":"crossref","first-page":"678","DOI":"10.4240\/wjgs.v13.i7.678","article-title":"Gastrectomy impact on the gut microbiome in patients with gastric cancer: a comprehensive review","volume":"13","author":"Maksimaityte","year":"2021","journal-title":"World J Gastrointest Surg"},{"issue":"8","key":"10.1016\/j.esmogo.2024.100048_bib63","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1136\/gutjnl-2019-319188","article-title":"Influence of gastrectomy for gastric cancer treatment on faecal microbiome and metabolome profiles","volume":"69","author":"Erawijantari","year":"2020","journal-title":"Gut"},{"issue":"11","key":"10.1016\/j.esmogo.2024.100048_bib64","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0206930","article-title":"The long-term effect of metabolic profile and microbiota status in early gastric cancer patients after subtotal gastrectomy","volume":"13","author":"Lin","year":"2018","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.esmogo.2024.100048_bib65","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/jso.21027","article-title":"Synchronous and metachronous cancers in patients with gastric cancer","volume":"98","author":"Eom","year":"2008","journal-title":"J\u00a0Surg Oncol"},{"key":"10.1016\/j.esmogo.2024.100048_bib66","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1186\/1471-2407-13-394","article-title":"Prediction of metachronous multiple primary cancers following the curative resection of gastric cancer","volume":"13","author":"Kim","year":"2013","journal-title":"BMC Cancer"},{"issue":"18","key":"10.1016\/j.esmogo.2024.100048_bib67","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.3748\/wjg.v28.i18.1981","article-title":"Fusobacterium nucleatum promotes colon cancer progression by changing the mucosal microbiota and colon transcriptome in a mouse model","volume":"28","author":"Wu","year":"2022","journal-title":"World J Gastroenterol"},{"issue":"6","key":"10.1016\/j.esmogo.2024.100048_bib68","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.tranon.2019.03.003","article-title":"Fusobacterium nucleatum contributes to the carcinogenesis of colorectal cancer by inducing inflammation and suppressing host immunity","volume":"12","author":"Wu","year":"2019","journal-title":"Transl Oncol"},{"issue":"8","key":"10.1016\/j.esmogo.2024.100048_bib69","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s00204-011-0648-7","article-title":"Carcinogenicity of deoxycholate, a secondary bile acid","volume":"85","author":"Bernstein","year":"2011","journal-title":"Arch Toxicol"},{"issue":"9","key":"10.1016\/j.esmogo.2024.100048_bib70","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1093\/ibd\/izaa342","article-title":"Alterations in bile acid metabolism associated with inflammatory bowel disease","volume":"27","author":"Li","year":"2021","journal-title":"Inflamm Bowel Dis"},{"issue":"13","key":"10.1016\/j.esmogo.2024.100048_bib71","doi-asserted-by":"crossref","first-page":"577","DOI":"10.12998\/wjcc.v6.i13.577","article-title":"Role of bile acids in colon carcinogenesis","volume":"6","author":"Nguyen","year":"2018","journal-title":"World J Clin Cases"},{"issue":"6005","key":"10.1016\/j.esmogo.2024.100048_bib72","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1126\/science.1191175","article-title":"Alleviating cancer drug toxicity by inhibiting a bacterial enzyme","volume":"330","author":"Wallace","year":"2010","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.esmogo.2024.100048_bib73","article-title":"The role of intestinal microbiota in development of irinotecan toxicity and in toxicity reduction through dietary fibres in rats","volume":"9","author":"Lin","year":"2014","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.esmogo.2024.100048_bib74","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrc1074","article-title":"5-Fluorouracil: mechanisms of action and clinical strategies","volume":"3","author":"Longley","year":"2003","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"10.1016\/j.esmogo.2024.100048_bib75","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.bcp.2008.04.019","article-title":"The cytostatic activity of pyrimidine nucleosides is strongly modulated by Mycoplasma hyorhinis infection: implications for cancer therapy","volume":"76","author":"Bronckaers","year":"2008","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"10.1016\/j.esmogo.2024.100048_bib76","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.cell.2017.07.008","article-title":"Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy","volume":"170","author":"Yu","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.esmogo.2024.100048_bib77","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.biopha.2018.08.165","article-title":"The influence of gut microbiota dysbiosis to the efficacy of 5-Fluorouracil treatment on colorectal cancer","volume":"108","author":"Yuan","year":"2018","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.esmogo.2024.100048_bib78","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.bbi.2019.02.020","article-title":"Impact of 5 fluorouracil chemotherapy on gut inflammation, functional parameters, and gut microbiota","volume":"80","author":"Sougiannis","year":"2019","journal-title":"Brain Behav Immun"},{"issue":"13","key":"10.1016\/j.esmogo.2024.100048_bib79","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1158\/1078-0432.CCR-20-4918","article-title":"Fecal microbiota transplantation from overweight or obese donors in cachectic patients with advanced gastroesophageal cancer: a randomized, double-blind, placebo-controlled, phase II study","volume":"27","author":"de Clercq","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.esmogo.2024.100048_bib80","doi-asserted-by":"crossref","first-page":"5642","DOI":"10.4238\/2015.May.25.16","article-title":"Well-balanced commensal microbiota contributes to anti-cancer response in a lung cancer mouse model","volume":"14","author":"Gui","year":"2015","journal-title":"Genet Mol Res"},{"issue":"6161","key":"10.1016\/j.esmogo.2024.100048_bib81","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1126\/science.1240527","article-title":"Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment","volume":"342","author":"Iida","year":"2013","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.esmogo.2024.100048_bib82","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.cmet.2021.03.002","article-title":"Gut microbial metabolites facilitate anticancer therapy efficacy by modulating cytotoxic CD8+ T cell immunity","volume":"33","author":"He","year":"2021","journal-title":"Cell Metab"},{"key":"10.1016\/j.esmogo.2024.100048_bib83","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1038\/nn.4606","article-title":"Gut microbiota is critical for the induction of chemotherapy-induced pain","volume":"20","author":"Shen","year":"2017","journal-title":"Nat Neurosci"},{"issue":"1","key":"10.1016\/j.esmogo.2024.100048_bib84","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12974-022-02523-w","article-title":"Gut microbiota depletion by antibiotics ameliorates somatic neuropathic pain induced by nerve injury, chemotherapy, and diabetes in mice","volume":"19","author":"Ma","year":"2022","journal-title":"J\u00a0Neuroinflammation"},{"issue":"1","key":"10.1016\/j.esmogo.2024.100048_bib85","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/1756-9966-32-67","article-title":"FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort","volume":"32","author":"Maugeri-Sacc\u00e0","year":"2013","journal-title":"J\u00a0Exp Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.esmogo.2024.100048_bib86","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.tiv.2005.06.045","article-title":"Pharmacogenetics of irinotecan metabolism and transport: an update","volume":"20","author":"Smith","year":"2006","journal-title":"Toxicol In\u00a0Vitro"},{"issue":"12","key":"10.1016\/j.esmogo.2024.100048_bib87","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.4161\/cbt.7.12.6940","article-title":"Faecal microflora and beta-glucuronidase expression are altered in an irinotecan-induced diarrhea model in rats","volume":"7","author":"Stringer","year":"2008","journal-title":"Cancer Biol Ther"},{"issue":"13","key":"10.1016\/j.esmogo.2024.100048_bib88","doi-asserted-by":"crossref","first-page":"7374","DOI":"10.1073\/pnas.1918095117","article-title":"Targeted inhibition of gut bacterial \u03b2-glucuronidase activity enhances anticancer drug efficacy","volume":"117","author":"Bhatt","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"suppl 2","key":"10.1016\/j.esmogo.2024.100048_bib89","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.3747\/co.27.5223","article-title":"A\u00a0review of cancer immunotherapy: from the past, to the present, to the future","volume":"27","author":"Esfahani","year":"2020","journal-title":"Curr Oncol"},{"issue":"5","key":"10.1016\/j.esmogo.2024.100048_bib90","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.annonc.2021.02.004","article-title":"Checkpoint inhibitors for gastroesophageal cancers: dissecting heterogeneity to better understand their role in first-line and adjuvant therapy","volume":"32","author":"Smyth","year":"2021","journal-title":"Ann Oncol"},{"issue":"10111","key":"10.1016\/j.esmogo.2024.100048_bib91","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","article-title":"Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Kang","year":"2017","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.esmogo.2024.100048_bib92","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.0013","article-title":"Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial","volume":"4","author":"Fuchs","year":"2018","journal-title":"JAMA Oncol"},{"issue":"7903","key":"10.1016\/j.esmogo.2024.100048_bib93","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/s41586-022-04508-4","article-title":"Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer","volume":"603","author":"Shitara","year":"2022","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.esmogo.2024.100048_bib94","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1001\/jamaoncol.2021.0275","article-title":"Assessment of pembrolizumab therapy for the treatment of microsatellite instability-high gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 clinical trials","volume":"7","author":"Chao","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmogo.2024.100048_bib95","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/s41422-020-0332-7","article-title":"Interaction between microbiota and immunity in health and disease","volume":"30","author":"Zheng","year":"2020","journal-title":"Cell Res"},{"issue":"3","key":"10.1016\/j.esmogo.2024.100048_bib96","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/j.1365-2249.2010.04217.x","article-title":"Increased programmed death-ligand-1 expression in human gastric epithelial cells in Helicobacter pylori infection","volume":"161","author":"Wu","year":"2010","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"10.1016\/j.esmogo.2024.100048_bib97","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00261-19","article-title":"Helicobacter pylori VacA targets myeloid cells in the gastric lamina propria to promote peripherally induced regulatory T-cell differentiation and persistent infection","volume":"10","author":"Altobelli","year":"2019","journal-title":"mBio"},{"issue":"9","key":"10.1016\/j.esmogo.2024.100048_bib98","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1136\/gutjnl-2014-307020","article-title":"A\u00a0pro-inflammatory role for Th22 cells in Helicobacter pylori-associated gastritis","volume":"64","author":"Zhuang","year":"2015","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.esmogo.2024.100048_bib99","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1136\/gutjnl-2020-323392","article-title":"Helicobacter pylori infection has a detrimental impact on the efficacy of cancer immunotherapies","volume":"71","author":"Oster","year":"2022","journal-title":"Gut"},{"issue":"79","key":"10.1016\/j.esmogo.2024.100048_bib100","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abq7001","article-title":"Silent recognition of flagellins from human gut commensal bacteria by Toll-like receptor 5","volume":"8","author":"Clasen","year":"2023","journal-title":"Sci Immunol"},{"issue":"10","key":"10.1016\/j.esmogo.2024.100048_bib101","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1158\/2326-6066.CIR-22-0107","article-title":"Gastric microbiome alterations are associated with decreased CD8+ tissue-resident memory T cells in the tumor microenvironment of gastric cancer","volume":"10","author":"Peng","year":"2022","journal-title":"Cancer Immunol Res"},{"issue":"6","key":"10.1016\/j.esmogo.2024.100048_bib102","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1038\/s41416-022-02112-x","article-title":"Intratumour Fusobacterium nucleatum and immune response to oesophageal cancer","volume":"128","author":"Kosumi","year":"2023","journal-title":"Br J Cancer"},{"issue":"suppl 3","key":"10.1016\/j.esmogo.2024.100048_bib103","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1200\/JCO.2021.39.3_suppl.161","article-title":"Genomic pathway of gut microbiome to predict efficacy of nivolumab in advanced gastric cancer: DELIVER trial (JACCRO GC-08)","volume":"39","author":"Sunakawa","year":"2021","journal-title":"JCO"}],"container-title":["ESMO Gastrointestinal Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949819824000098?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949819824000098?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T06:40:32Z","timestamp":1719988832000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949819824000098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":103,"alternative-id":["S2949819824000098"],"URL":"https:\/\/doi.org\/10.1016\/j.esmogo.2024.100048","relation":{},"ISSN":["2949-8198"],"issn-type":[{"value":"2949-8198","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of the microbiome in the development and treatment of gastric cancer: an overview of the biological and clinical landscape","name":"articletitle","label":"Article Title"},{"value":"ESMO Gastrointestinal Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmogo.2024.100048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100048"}}